Evidence map›Paper›PMID 32112596›Full record

ArticleJournal of veterinary internal medicine2020

Renin-angiotensin aldosterone profile before and after angiotensin-converting enzyme-inhibitor administration in dogs with angiotensin-converting enzyme gene polymorphism.

Darcy Adin, Clarke Atkins, Oliver Domenig, Teresa DeFrancesco, Bruce Keene, Sandra Tou, Joshua A Stern, Kathryn M Meurs

Open access · goldAbstract read
In one paragraph

Article in Journal of veterinary internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Angiotensin Dysregulation in Patients with Arterial Aneurysms.International journal of molecular sciences · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. The Role of Personalized Medicine in Companion Animal Cardiology.The Veterinary clinics of North America. Small animal practice · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Darcy AdinCollege of Veterinary Medicine, University of Florida, Gainesville, Florida.ORCID https://orcid.org/0000-0003-0972-0365
Clarke AtkinsCollege of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
Oliver DomenigAttoquant Diagnostics, Vienna, Austria.
Teresa DeFrancescoCollege of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.ORCID https://orcid.org/0000-0002-3663-3323
Bruce KeeneCollege of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
Sandra TouCollege of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
Joshua A SternDepartment of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California.
Kathryn M MeursCollege of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
North Carolina State University · USLudwig Boltzmann Institute Applied Diagnostics · ATUniversity of California, Davis · USUniversity of Florida · US

Funding

Morris Animal Foundation D14CA-810University of Florida Open Access Publishing Fund
6 · The paper itself

Abstract

backgroundAn angiotensin-converting enzyme (ACE) gene polymorphism occurs in dogs; however, functional importance is not well studied. HYPOTHESIS: We hypothesized that dogs with the polymorphism would show alternative renin-angiotensin aldosterone system (RAAS) pathway activation and classical RAAS pathway suppression before and after ACE-inhibitor administration, as compared to dogs without the polymorphism that would show this pattern only after ACE-inhibitor administration. ANIMALS: Twenty-one dogs with mitral valve disease that were genotyped for the ACE gene polymorphism.

methodsThis retrospective study utilized stored samples from 8 ACE gene polymorphism-negative (PN) dogs and 13 ACE gene polymorphism-positive (PP) dogs before and after enalapril administration. Equilibrium analysis was performed to evaluate serum RAAS metabolites and enzyme activities. Results were compared before and after enalapril, and between groups.

resultsThe classical RAAS pathway was suppressed and the alternative RAAS pathway was enhanced for both genotypes after administration of enalapril, with no differences before enalapril administration. Aldosterone breakthrough occurred in both PN (38%) and PP (54%) dogs despite angiotensin II suppression. Aldosterone was significantly higher (P = .02) in ACE gene PP dogs (median, 92.17 pM; IQR, 21.85-184.70) compared to ACE gene PN dogs (median, 15.91 pM; IQR, <15.00-33.92) after enalapril. CONCLUSIONS AND CLINICAL IMPORTANCE: The ACE gene polymorphism did not alter baseline RAAS activity. Aldosterone breatkthrough in some dogs suggests nonangiotensin mediated aldosterone production that might be negatively influenced by genotype. These results support the use of aldosterone receptor antagonists with ACE-inhibitors when RAAS inhibition is indicated for dogs, especially those positive for the ACE gene polymorphism.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAnimalsDog DiseasesDogsGenetic Predisposition to DiseaseGenotypeHumansMitral Valve ProlapsePeptidyl-Dipeptidase APolymorphism, GeneticRenin-Angiotensin SystemRetrospective StudiesAngiotensin-Converting Enzyme InhibitorsPeptidyl-Dipeptidase AACE-inhibitorenalaprilgenotypepharmacogeneticpharmacogenomic

Identifiers

PMID32112596
PMCPMC7097578
OpenAlexW3007803872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.